ADRB2 and cancer: As is shown in Figure 1, hyperactive β-AR signaling in response to systemic and autocrine increases in their physiological agonists thus further intensifies the cancer-stimulating signaling pathways that are additionally activated by the presence of constitutively active K-Ras.